GENIE BPC PANC v1.0-public dataset

The GENIE Biopharma Collaborative (BPC) PANC v1.0-public dataset contains 1,109 PANC patients from four institutions:

• Memorial Sloan Kettering Cancer Center
• Dana-Farber Cancer Institute
• Princess Margaret Cancer Centre
• Vanderbilt-Ingram Cancer Center

Anticipated Release: First quarter 2024

Download the AACR Project GENIE BPC Pancreatic Cancer Overview

Contents of GENIE BPC Data

• Genomic Data: Clinical-grade next-generation sequencing data for each patient from the GENIE Registry. Genomic profiling was performed between 2014 and 2018.
• Treatment Histories: All anti-neoplastic systemic therapies–intravenous and oral chemotherapies–are included in the data set. Dates are provided as intervals from diagnosis to start and stop of each drug. Investigational drugs are masked, no dosing information is included.
• PRISSMM™: the BPC PANC dataset uses the PRISSMM™ framework developed at the Dana-Farber Cancer Institute to determine outcomes from retrospective real-world data to ascertain cancer treatment responses in the real world.
• Pathologic Information: Each pathology specimen from diagnosis through death or last follow-up is curated with specimen type, site, and histology.
• Imaging Information: Each CT, MRI, PET-CT scan from diagnosis through death or last follow-up is curated for the presence or absence of cancer and an evaluation of whether the cancer was stable, responding, or progressing. These data are used to compute progression-free survival-imaging (PFS-I). Sites of tumor involvement are also recorded.
• Medical Oncologist’s Evaluations: Medical oncology notes (one/month) have been curated to ascertain the presence or absence of cancer and whether the cancer was stable, responding, or progressing. These data are used to compute progression-free survival-medonc (PFS-M) from diagnosis through death or date of last follow-up.
• Radiation Information: All radiation therapies are included in the data set, including dose and fraction received. Dates are provided as intervals from diagnosis to start and stop of radiation therapy.
• Additional relevant biomarkers: Information about select biomarkers not included on the NGS panels, including PDL1, MMR, and ER/PR/HER2, are also curated.
• There are no patient (self-) reported outcomes in the data.
• PANC cancer diagnosis is considered the index tumor for this patient cohort. There are data about other cancer diagnoses antecedent to the PANC and subsequent to the PANC.
• Overall survival is based on death with censoring at date of last contact known alive. Ascertainment of death varies by institution.
• Exact date fields have been masked to preserve confidentiality. However, exact date intervals are available and allow for calculation of the time between events, e.g., diagnosis, treatment start, treatment end, PFS-I, PFS-M, OS, etc.